AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 211 min read$IART

Integra LifeSciences Q3 earnings beat estimates, but revenue falls short (IART:NASDAQ)

Integra LifeSciences (IART) reported Q3 Non-GAAP EPS of $0.59, beating estimates by $0.03, but revenue of $411.2M missed expectations by $0.9M. The company guided Q4 revenue to $413M–$433M, below consensus of $432.21M, and adjusted EPS to $0.61–$0.71.

Original reporting
seekingalpha.com
Published Oct 21, 2026, 10:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings beat and revenue miss provide fresh data for traders to adjust positions before the market opens.

02

Market read

First‑time earnings release with mixed results; likely influences short‑term price action.

03

What to watch

Potential cost‑control measures or upcoming product launches not disclosed may mitigate revenue concerns.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences released its Q3 earnings, marking the first public disclosure of these results.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Q3 non‑GAAP EPS of $0.59 beat estimates while revenue of $411.2M missed by $0.9M; Q4 revenue guidance of $413M‑$433M is below consensus.

Expected impact

likely modest pressure as investors price in the revenue shortfall despite earnings beat

Evidence & confidence

Revenue fell short of expectations, a key driver for valuation, while EPS beat offers limited upside; market typically reacts more to top‑line misses.

Market effects

Sector

Medical device sector may see slight pullback as a peer reports weaker revenue growth.

Regional

U.S. biotech/medical device stocks could experience modest volatility in early trading.

Global

Limited to investors tracking earnings season; no broader macro impact.

Counterpoint

What could challenge this read

The EPS beat suggests operational efficiency; the stock could rebound if guidance is revised upward.

Key entities

  • company
    Integra LifeSciences Holdings Corporation

    Medical device and surgical equipment manufacturer.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min